Literature DB >> 20467360

Epidemiology of Graves' orbitopathy.

Sudeep Putta-Manohar1, Petros Perros.   

Abstract

Thyroid orbitopathy is a relatively rare disease. Prevalence data are lacking and can only be estimated. The incidence of thyroid orbitopathy has been documented in one American study (16 cases per 100,000 population per year for females and 2.9 cases per 100,000 population for males). Thyroid orbitopathy can affect every race and age group. The majority of patients present in middle age with concurrent thyrotoxicosis due to Graves' disease. The onset of orbitopathy usually coincides with the hyperthyroidism, though the two may be asynchronous by months or sometimes years. A small proportion of patients with thyroid orbitopathy have primary hypothyroidism or are euthyroid. Female patients outnumber males by 2-5 to 1. Smoking increases the risk of thyroid orbitopathy up to 8-fold.

Entities:  

Mesh:

Year:  2010        PMID: 20467360

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  4 in total

Review 1.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

2.  Age differences in clinical manifestation and prognosis of thyroid eye disease.

Authors:  Guy J Ben Simon; Gabriel Katz; Ofira Zloto; Hana Leiba; Beatrix Hadas; Ruth Huna-Baron
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-09-07       Impact factor: 3.117

3.  BIOINFORMATIC ANALYSIS IDENTIFIES POTENTIALLY KEY DIFFERENTIALLY EXPRESSED GENES AND PATHWAYS IN ORBITAL ADIPOSE TISSUES OF PATIENTS WITH THYROID EYE DISEASE.

Authors:  F F Zhu; L Z Yang
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jan-Mar       Impact factor: 0.877

4.  Predictive Factors of Development of Graves' Ophthalmopathy for Patients with Juvenile Graves' Disease.

Authors:  Dalia Jarusaitiene; Rasa Verkauskiene; Vytautas Jasinskas; Jurate Jankauskiene
Journal:  Int J Endocrinol       Date:  2016-06-16       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.